Lupin's Novel Laboratories knocked by FDA for cleanliness, quality issues at New Jersey plant - fiercepharma.com
FDA cited Lupin's Novel Laboratories for cleanliness and quality issues at their New Jersey plant, indicating potential compliance failures.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, especially those operating under cGMP regulations. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action required to address compliance issues; no specific deadline provided.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA's findings highlight significant cleanliness and quality control issues that could affect product safety and compliance.
Who it affects
All pharmaceutical manufacturers, especially those operating under cGMP regulations.
What you must do
Review and rectify cleanliness and quality control processes to meet FDA standards.
Deadline
Immediate action required to address compliance issues; no specific deadline provided.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com
- Psychedelics Policy Newsletter: DEA considers rescheduling psilocybin, FDA releases rejection decision, and more - reason.org